Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy

참고문헌 (170)

1. Zane, L., "Common features of chromatin in aging and cancer: cause or coincidence?", Trends Cell Biol, 24, pp.686~694 (2014)
2. Schaaf, M. B., "Defining the role of the tumor vasculature in antitumor immunity and immunotherapy", Cell Death Dis, 9, pp.115~ (2018)
3. Hanahan, D., "Accessories to the crime : functions of cells recruited to the tumor microenvironment", Cancer Cell, 21, pp.309~322 (2012)
4. Hyeon, D. Y., "Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes", Nat. Cancer, 4, pp.290~307 (2023)
5. Ganss, R., "Mini-review: Overcoming tumor-intrinsic resistance to immune effector function", Eur. J. Immunol, 34, pp.2635~2641 (2004)
6. Hinshaw, D. C., "The tumor microenvironment innately modulates cancer progression", Cancer Res, 79, pp.4557~4566 (2019)
7. Turley, S. J., "Immunological hallmarks of stromal cells in the tumour microenvironment", Nat. Rev. Immunol, 15, pp.669~682 (2015)
8. Munn, L. L., "Vascular regulation of antitumor immunity", Science, 365, pp.544~545 (2019)
9. Suwa Tatsuya, "Tumor microenvironment and radioresistance", Experimental and Molecular Medicine, 53, pp.1~7 (2021), 생화학분자생물학회[DOI]
10. Huang, Y., "Vascular normalization as an emerging strategy to enhance cancer immunotherapy", Cancer Res, 73, pp.2943~2948 (2013)
11. Martin, J. D., "Normalizing function of tumor vessels : progress, opportunities, and challenges", Annu. Rev. Physiol, 81, pp.505~534 (2019)
12. Whatcott, C. J., "Orchestrating the tumor microenvironment to improve survival for patients with pancreatic cancer : normalization, not destruction", Cancer J, 21, pp.299~306 (2015)
13. Zheng, J., "Toward normalization of the tumor microenvironment for cancer therapy", Integr. Cancer Ther, 18, pp.1534735419862352~ (2019)
14. Jain, R. K., "Normalization of tumor vasculature : an emerging concept in antiangiogenic therapy", Science, 307, pp.58~62 (2005)
15. Binnewies, M., "Understanding the tumor immune microenvironment(TIME)for effective therapy", Nat. Med, 24, pp.541~550 (2018)
16. Welti, J., "Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer", J. Clin. Invest, 123, pp.3190~3200 (2013)
17. Carmeliet, P., "Angiogenesis in cancer and other diseases", Nature, 407, pp.249~257 (2000)
18. Hanahan, D., "Hallmarks of cancer : The next generation", Cell, 144, pp.646~674 (2011)
19. Baeriswyl, V., "The angiogenic switch in carcinogenesis", Semin. Cancer Biol, 19, pp.329~337 (2009)
20. Weis, S. M., "Tumor angiogenesis : molecular pathways and therapeutic targets", Nat. Med, 17, pp.1359~1370 (2011)
21. Jain, R. K, "Normalizing tumor microenvironment to treat cancer : bench to bedside to biomarkers", J. Clin. Oncol, 31, pp.2205~2218 (2013)
22. Motz, G. T., "The parallel lives of angiogenesis and immunosuppression : cancer and other tales", Nat. Rev. Immunol, 11, pp.702~711 (2011)
23. Zhang, N., "DLL1 orchestrates CD8+ T cells to induce long-term vascular normalization and tumor regression", Proc. Natl. Acad. Sci. USA, 118, pp.e2020057118~ (2021)
24. Jain, R. K., "The role of mechanical forces in tumor growth and therapy", Annu. Rev. Biomed. Eng, 16, pp.321~346 (2014)
25. Noman, M. Z., "Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia", Am. J. Physiology-Cell Physiol, 309, pp.C569~C579 (2015)
26. Pereira, B. A., "CAF subpopulations : a new reservoir of stromal targets in pancreatic cancer", Trends Cancer, 5, pp.724~741 (2019)
27. Costa, A., "Fibroblast heterogeneity and immunosuppressive environment in human breast cancer", Cancer Cell, 33, pp.463~479 (2018)
28. Yang Dakai, "Cancer-associated fibroblasts: from basic science to anticancer therapy", Experimental and Molecular Medicine, 55, pp.1322~1332 (2023), 생화학분자생물학회[DOI]
29. Abou Khouzam, R., "Tumor hypoxia regulates immune escape", invasion : influence on angiogenesis and potential impact of hypoxic biomarkers on cancer therapies, 2021, pp.11, 613114~
30. Rankin, E. B, "Hypoxic control of metastasis", Science, 352, pp.175~180 (2016)
31. Sørensen, B. S., "Tumor hypoxia : impact on radiation therapy and molecular pathways", Front. Oncol, 10, pp.562~ (2020)
32. Cosse, J. P., "Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression", Anticancer Agents Med. Chem, 8, pp.790~797 (2008)
33. Jayaprakash, P., "Hypoxia reduction sensitizes refractory cancers to immunotherapy", Annu. Rev. Med, 73, pp.251~265 (2022)
34. Folkman, J., "Tumor angiogenesis : therapeutic implications", N. Engl. J. Med, 285, pp.1182~1186 (1971)
35. Kim, K. J., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo", Nature, 362, pp.841~844 (1993)
36. Stylianopoulos, T., "Combining two strategies to improve perfusion and drug delivery in solid tumors", Proc. Natl Acad. Sci. USA, 110, pp.18632~18637 (2013)
37. Jayson, G. C., "Antiangiogenic therapy in oncology: current status and future directions", Lancet, 388, pp.518~529 (2016)
38. Jain, R. K., "Normalizing tumor vasculature with anti-angiogenic therapy : A new paradigm for combination therapy", Nat. Med, 7, pp.987~989 (2001)
39. Goel, S., "Normalization of the vasculature for treatment of cancer and other diseases", Physiol. Rev, 91, pp.1071~1121 (2011)
40. Jain, R. K., "Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia", Cancer Cell, 26, pp.605~622 (2014)
41. Huang, Y., "Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy", Proc. Natl Acad. Sci. USA, 109, pp.17561~17566 (2012)
42. Zhao, X. C., "Inhibition of tumor angiogenesis and tumor growth by the DSL domain of human Delta-like 1 targeted to vascular endothelial cells", Neoplasia, 15, pp.815~825 (2013)
43. Zhang, J. P., "Overexpression of Notch ligand Dll1 in B16 melanoma cells leads to reduced tumor growth due to attenuated vascularization", Cancer Lett, 309, pp.220~227 (2011)
44. Tolaney, S. M., "Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients", Proc. Natl Acad. Sci. USA, 112, pp.14325~14330 (2015)
45. Ma, J, "Combination of antiangiogenesis with chemotherapy for more effective cancer treatment", Mol. Cancer Ther, 7, pp.3670~3684 (2008)
46. Winkler, F., "Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation : role of oxygenation, angiopoietin-1, and matrix metalloproteinases", Cancer Cell, 6, pp.553~563 (2004)
47. Huang, Y., "Improving immune–vascular crosstalk for cancer immunotherapy", Nat. Rev. Immunol, 18, pp.195~203 (2018)
48. Khan, K. A., "Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa", Nat. Rev. Clin. Oncol, 15, pp.310~324 (2018)
49. Taal, W., "Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma(BELOB trial) : a randomised controlled phase 2 trial", Lancet Oncol, 15, pp.943~953 (2014)
50. Rak, J. W., "Consequences of angiogenesis for tumor progression, metastasis and cancer therapy", Anti-Cancer Drug, 6, pp.3~18 (1995)
51. Kerbel, R. S., "Tumor angiogenesis", N. Engl. J. Med, 358, pp.2039~2049 (2008)
52. Yuan, F., "Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor", vascular permeability factor antibody, 1996, pp.93, 14765~14770
53. Wildiers, H., "Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11", Brit. J. Cancer, 88, pp.1979~1986 (2003)
54. Ferrara, N., "Bevacizumab(Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy", Biochem. Biophys. Res. Co, 333, pp.328~335 (2005)
55. Fukumura, D., "Enhancing cancer immunotherapy using antiangiogenics : opportunities and challenges", Nat. Rev. Clin. Oncol, 15, pp.325~340 (2018)
56. Dings, R. P., "Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization", Clin. Cancer Res, 13, pp.3395~3402 (2007)
57. Min Hye-Young, "Molecular targeted therapy for anticancer treatment", Experimental and Molecular Medicine, 54, pp.1~25 (2022), 생화학분자생물학회[DOI]
58. Dvorak, H. F, "Vascular permeability factor", vascular endothelial growth factor : a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy, 2002, pp.20, 4368~4380
59. Chauhan, V. P., "Nano-Enabled Medical Applications", pp.279~311 (2020), Jenny Stanford Publishing
60. Tong, R. T., "Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors", Cancer Res, 64, pp.3731~3736 (2004)
61. Wu, J.-b, "Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy", OncoTargets. Ther, 11, pp.6901~6909 (2018)
62. Gotink, K. J., "Anti-angiogenic tyrosine kinase inhibitors : what is their mechanism of action?", Angiogenesis, 13, pp.1~14 (2010)
63. Batra, S., "MRI assessment of angiogenesis inhibitor sunitinib’s influence on tumor oxygenation to identify an optimal chemoradiotherapeutic window", Int. J. Radiat. Oncol, 75, pp.S43~ (2009)
64. Zhou, Q., "Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model", Neuro-Oncology, 11, pp.301~310 (2009)
65. Saharinen, P., "VEGF and angiopoietin signaling in tumor angiogenesis and metastasis", Trends. Mol. Med, 17, pp.347~362 (2011)
66. Holash, J., "Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF", Science, 284, pp.1994~1998 (1999)
67. Nasarre, P., "Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth", Cancer Res, 69, pp.1324~1333 (2009)
68. Peterson, T. E., "Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages", Proc. Natl Acad. Sci, 113, pp.4470~4475 (2016)
69. Kloepper, J., "Ang-2", VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival, 2016, pp.113, 4476~4481
70. Han, S., "Amelioration of sepsis by TIE2 activation induced vascular protection", Sci. Transl. Med, 8, pp.335ra355~335ra355 (2016)
71. Park, J. -S., "Normalization of Tumor Vessels by Tie2 Activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment", Cancer Cell, 30, pp.953~967 (2016)
72. Radtke, F., "Regulation of innate and adaptive immunity by Notch", Nat. Rev. Immunol, 13, pp.427~437 (2013)
73. Thurston, G., "The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth", Nat. Rev. Cancer, 7, pp.327~331 (2007)
74. Yan, M., "Delta-like 4", Notch signaling and its therapeutic implications, 2007, pp.13, 7243~7246
75. Patel, N. S., "Up-Regulation of Endothelial Delta-like 4 Expression Correlates with Vessel Maturation in Bladder Cancer", Clin. Cancer Res, 12, pp.4836~4844 (2006)
76. Yan, M., "Chronic DLL4 blockade induces vascular neoplasms", Nature, 463, pp.E6~E7 (2010)
77. Yan, X. -Q., "A novel Notch ligand, Dll4, induces T-cell leukemia", lymphoma when overexpressed in mice by retroviral-mediated gene transfer, 2001, pp.98, 3793~3799
78. Vogelstein, B., "Cancer genes and the pathways they control", Nat. Med, 10, pp.789~799 (2004)
79. Karar, J., "PI3K", AKT, Front. Mol. Neurosci, pp.2011, 4[DOI]
80. Cerniglia, G. J., "Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy", PLoS One, 4, pp.e6539~ (2009)
81. Serban, D., "H-Ras regulates angiogenesis and vascular permeability by activation of distinct downstream effectors", Circ. Res, 102, pp.1350~1358 (2008)
82. Cohen, L. H., "Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics", Biochem. Pharmacol, 60, pp.1061~1068 (2000)
83. Cohen-Jonathan, E., "The farnesyltransferase inhibitor L744, 832 reduces hypoxia in tumors expressing activated H-ras", Cancer Res, 61, pp.2289~2293 (2001)
84. Delmas, C., "The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft", Clin. Cancer Res, 9, pp.6062~6068 (2003)
85. Pore, N., "Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation : implications for radiotherapy", Cancer Res, 66, pp.9252~9259 (2006)
86. Qayum, N., "Tumor vascular changes mediated by inhibition of oncogenic signaling", Cancer Res, 69, pp.6347~6354 (2009)
87. Ma, P. C., "C-Met : structure, functions and potential for therapeutic inhibition", Cancer Metastasis Rev, 22, pp.309~325 (2003)
88. Lee, J. -H., "A novel germ line juxtamembrane Met mutation in human gastric cancer", Oncogene, 19, pp.4947~4953 (2000)
89. Birchmeier, C., "Met, metastasis, motility and more", Nat. Rev. Mol. Cell Biol, 4, pp.915~925 (2003)
90. Comoglio, P. M., "Drug development of MET inhibitors : targeting oncogene addiction and expedience", Nat. Rev. Drug Discov, 7, pp.504~516 (2008)
91. Xin, X., "Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo", Am. J. Pathol, 158, pp.1111~1120 (2001)
92. Shojaei, F., "HGF", c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors, 2010, pp.70, 10090~10100
93. Cascone, T., "The HGF", c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer, 2017, pp.23, 5489~5501
94. Benkhoucha, M., "Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+ Foxp3+ regulatory T cells", Proc. Natl Acad. Sci. USA, 107, pp.6424~6429 (2010)
95. Tian, L., "Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming", Nature, 544, pp.250~254 (2017)
96. De Palma, M., "CD4+ T cell activation and vascular normalization : two sides of the same coin?", Immunity, 46, pp.773~775 (2017)
97. Ong, T., "Ratio of angiopoietin-2 to angiopoietin-1 as a predictor of mortality in acute lung injury patients", Crit. Care Med, 38, pp.1845~1851 (2010)
98. Zheng, X., "CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils", Int. J. Cancer, 146, pp.1730~1740 (2020)
99. Zhang, Y., "Vascular normalization was associated with colorectal tumor regression upon anti-PD-L1 combinational therapy", J. Immunol. Res, 2023, pp.5867047~ (2023)[DOI]
100. Walford, G., "Nitric oxide in vascular biology", J. Thromb. Haemost, 1, pp.2112~2118 (2003)
101. Sung, Y. -C., "Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies", Nat, Nanotechnol, 14, pp.1160~1169 (2019)
102. Papageorgis, P., "Tranilast-induced stress alleviation in solid tumors improves the efficacy of chemo-and nanotherapeutics in a size-independent manner", Sci. Rep, 7, pp.46140~ (2017)
103. Klug, F., "Low-dose irradiation programs macrophage differentiation to an iNOS+", M1 phenotype that orchestrates effective T cell immunotherapy, 2013, pp.24, 589~602
104. Ho, Y. J., "Normalization of tumor vasculature by oxygen microbubbles with ultrasound", Theranostics, 9, pp.7370~7383 (2019)
105. Matejuk, A., "MicroRNAs and tumor vasculature normalization : impact on anti-tumor immune response", Arch. Immunol. Ther. Exp, 61, pp.285~299 (2013)
106. Drake, C. G., "Advances in Immunology Vol. 90", pp.51~81 (2006), Academic Press
107. Voron, T., "VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors", J. Exp. Med, 212, pp.139~148 (2015)
108. Gabrilovich, D. I., "Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells", Nat. Med, 2, pp.1096~1103 (1996)
109. Gabrilovich, D., "Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo", Blood, 92, pp.4150~4166 (1998)
110. Swartz, M. A., "Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity", Nat. Rev. Cancer, 12, pp.210~219 (2012)
111. Sanmamed, M. F., "A paradigm shift in cancer immunotherapy : from enhancement to normalization", Cell, 175, pp.313~326 (2018)
112. Fritz, J. M., "Development of immune checkpoint therapy for cancer", J. Exp. Med, 216, pp.1244~1254 (2019)
113. Sobhani, N., "CTLA-4 in regulatory T cells for cancer immunotherapy", Cancers, 13, pp.1440~ (2021)
114. Han, Y., "PD-1", PD-L1 pathway : current researches in cancer, 2020, pp.10, 727~
115. LV, B., "Immunotherapy : reshape the tumor immune microenvironment", Front. Immunol, 13, pp.844142~ (2022)[DOI]
116. Jahchan, N. S., "Tuning the tumor myeloid microenvironment to fight cancer", Front. Immunol, 10, pp.1611~ (2019)[DOI]
117. Jung, K., "Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy", J. Clin. Invest, 127, pp.3039~3051 (2017)
118. Jung, K., "Targeting CXCR4-dependent immunosuppressive Ly6C(low)monocytes improves antiangiogenic therapy in colorectal cancer", Proc. Natl Acad. Sci. USA, 114, pp.10455~10460 (2017)
119. Ries, C. H., "Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy", Cancer Cell, 25, pp.846~859 (2014)
120. Jeong, J., "Context drives diversification of monocytes and neutrophils in orchestrating the tumor microenvironment", Front. Immunol, 10, pp.1817~ (2019)[DOI]
121. Qian, B. -Z., "CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis", Nature, 475, pp.222~225 (2011)
122. Kalbasi, A., "Tumor-derived CCL2 mediates resistance to radiotherapy in pancreatic ductal adenocarcinoma", Clin. Cancer Res, 23, pp.137~148 (2017)
123. Sanford, D. E., "Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer : a role for targeting the CCL2", CCR2 Axis, 2013, pp.19, 3404~3415
124. Bonapace, L., "Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis", Nature, 515, pp.130~133 (2014)
125. Long, K. B., "IFNγ and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma", Cancer Discov, 6, pp.400~413 (2016)
126. Hanna, R. N., "Patrolling monocytes control tumor metastasis to the lung", Science, 350, pp.985~990 (2015)
127. Kubo, H., "Primary tumors limit metastasis formation through induction of IL15-mediated cross-talk between patrolling monocytes and NK cells", Cancer Immunol. Res, 5, pp.812~820 (2017)
128. 정주희, "Tumor-Infiltrating Neutrophils and Non-Classical Monocytes May Be Potential Therapeutic Targets for HER2 negative Gastric Cancer", Immune Network, 21(4), pp.1~16 (2021), 대한면역학회[DOI]
129. Kwak Su-Bin, "Tumor regionalization after surgery: Roles of the tumor microenvironment and neutrophil extracellular traps", Experimental and Molecular Medicine, 54, pp.720~729 (2022), 생화학분자생물학회[DOI]
130. Rayes, R. F., "Primary tumors induce neutrophil extracellular traps with targetable metastasis-promoting effects", JCI Insight, 4 (2019)[DOI]
131. Yuan, Z. Y., "High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis", Onco. Targets Ther, 7, pp.1475~1480 (2014)
132. Henze, A. T., "The impact of hypoxia on tumor-associated macrophages", J. Clin. Invest, 126, pp.3672~3679 (2016)
133. Nywening, T. M., "Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer : a single-centre, open-label, dose-finding, non-randomised, phase 1b trial", Lancet Oncol, 17, pp.651~662 (2016)
134. Petty, A. J., "Targeting Tumor-Associated Macrophages in Cancer Immunotherapy", Cancers (Basel), 13 (2021)[DOI]
135. Kim, J., "Novel endogenous endoplasmic reticulum transmembrane protein SURF4 suppresses cell death by negatively regulating the STING-STAT6 axis in myeloid leukemia", Cancer Commun. (Lond.), 43, pp.395~399 (2023)
136. Woo, S. Y., "Role of reactive oxygen species in regulating 27-hydroxycholesterol-induced apoptosis of hematopoietic progenitor cells and myeloid cell lines", Cell Death Dis, 13, pp.916~ (2022)
137. Döhner, H., "Acute myeloid leukemia", N. Engl. J. Med, 3, pp.1136~1152 (2015)
138. Beyar-Katz, O., "Novel approaches to acute myeloid leukemia immunotherapy", Clin. Cancer Res, 24, pp.5502~5515 (2018)
139. Faderl, S., "The biology of chronic myeloid leukemia", N. Engl. J. Med, 341, pp.164~172 (1999)
140. Ilander, M., "Immunology and immunotherapy of chronic myeloid leukemia", Curr. Hematol. Malig. Rep, 9, pp.17~23 (2014)
141. Cao, G. -D., "The oncolytic virus in cancer diagnosis and treatment", Front. Oncol, 10, pp.1786~ (2020)[DOI]
142. Zheng, M., "Oncolytic viruses for cancer therapy : barriers and recent advances", Molecular Therapy-Oncolytics, 15, pp.234~247 (2019)
143. Conlon, K. C., "Cytokines in the treatment of cancer", J. Interf. Cytok. Res, 39, pp.6~21 (2019)
144. Kirkwood, J. M., "Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma", Semin. Oncol, 24, pp.S16~S23 (1997)
145. Klapper, J. A., "High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006", Cancer, 113, pp.293~301 (2008)
146. Davar, D., "High-dose interleukin-2(HD IL-2)for advanced melanoma : a single center experience from the University of Pittsburgh Cancer Institute", J. Immunother. Cancer, 5, pp.74~ (2017)
147. Huang, L., "Mild photothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy", Nat. Commun, 10, pp.4871~ (2019)
148. Rosenberg, S. A., "Adoptive cell transfer: a clinical path to effective cancer immunotherapy", Nat. Rev. Cancer, 8, pp.299~308 (2008)
149. Sterner, R. C., "CAR-T cell therapy : current limitations and potential strategies", Blood Cancer J, 11, pp.69~ (2021)
150. Benmebarek, M. R., "Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells", Int. J. Mol. Sci, 20 (2019)
151. Kochenderfer, J. N., "Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19", Blood, 116, pp.4099~4102 (2010)
152. Safarzadeh Kozani, P., "Recent Advances in Solid Tumor CAR-T Cell Therapy : Driving Tumor Cells From Hero to Zero? Front", Immunol, 13 (2022)[DOI]
153. Moon, E. K., "Expression of a Functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human t cells expressing a mesothelin-specific chimeric antibody receptor", Clin. Cancer Res, 17, pp.4719~4730 (2011)
154. Caruana, I., "Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes", Nat. Med, 21, pp.524~529 (2015)
155. Saxena, M., "Therapeutic cancer vaccines", Nat. Rev. Cancer, 21, pp.360~378 (2021)
156. Higano, C. S., "Sipuleucel-T", Nat. Rev. Drug Discov, 9, pp.513~514 (2010)
157. Ali, O. A., "Vaccines combined with immune checkpoint antibodies promote cytotoxic t-cell activity and tumor eradication", Cancer Immunol. Res, 4, pp.95~100 (2016)
158. Minji Choi, "Immunogenic cell death in cancer immunotherapy", BMB Reports, 56(5), pp.275~286 (2023), 생화학분자생물학회
159. Krysko, D. V., "Immunogenic cell death and DAMPs in cancer therapy", Nat. Rev. Cancer, 12, pp.860~875 (2012)
160. Kroemer, G., "Immunogenic cell death in cancer therapy", Annu. Rev. Immunol, 31, pp.51~72 (2013)
161. Vanmeerbeek, I., "Trial watch : chemotherapy-induced immunogenic cell death in immuno-oncology", Oncoimmunology, 9, pp.1703449~ (2020)
162. Demaria, O., "STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity", Proc. Natl Acad. Sci. USA, 112, pp.15408~15413 (2015)
163. Yang, H., "STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade", J. Clin. Invest, 129, pp.4350~4364 (2019)
164. Ribatti, D., "Vascular normalization : a real benefit? Cancer Chemother", Pharm, 68, pp.275~278 (2011)
165. Arjaans, M., "Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake", Cancer Res, 73, pp.3347~3355 (2013)
166. Cassier, P. A., "CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue : a dose-escalation and dose-expansion phase 1 study", Lancet Oncol, 16, pp.949~956 (2015)
167. Papadopoulos, K. P., "First-in-human study of AMG 820, a monoclonal anti-colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumors", Clin. Cancer Res, 23, pp.5703~5710 (2017)
168. Kim, C., "MarcoPolo: a method to discover differentially expressed genes in single-cell RNA-seq data without depending on prior clustering", Nucleic Acids Res, 50, pp.e71~e71 (2022)[DOI]
169. Zhang, T., "Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma", Cell Death Dis, 13, pp.897~ (2022)
170. Kim, D. K., "PD-L1-directed PlGF", VEGF blockade synergizes with chemotherapy by targeting CD141+ cancer-associated fibroblasts in pancreatic cancer, 2022, pp.13, 6292~

관련 논문AI추천